News & Updates

Show Multimedia Only

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

24 Jun 2021 by

The use of apremilast consistently reduced the number and pain due to oral ulcers in both men and women with active Behçet’s syndrome, according to a subgroup analysis of the RELIEF* study presented at EULAR 2021.

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

24 Jun 2021

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

23 Jun 2021 by

Analysis of the German COVID-19 registry suggests that patients with rheumatic or musculoskeletal diseases (RMDs) who are treated with tumour necrosis factor (TNF) inhibitors appear to be at lower risk of severe outcomes of COVID-19 compared with those treated with other (non-TNF inhibitor) immunomodulatory treatments (OIDs).

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

23 Jun 2021

News & Updates

Showing Rheumatology articles

Showing

Specialty:

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization